BUSINESS● LOWOct 1 · Oct 1, 2026, 8:54 AM
Teva and Samsung Bioepis partner on up to six biosimilars
Seeking Alpha Tech · global
Teva and Samsung Bioepis have announced a partnership to collaborate on the development of up to six biosimilar products. This alliance represents a strategic move in the pharmaceutical industry to expand their biosimilar portfolios.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS36m agoAnthropic nearing second $45B deal with Nscale for compute power: reportSeeking Alpha TechBUSINESS41m agoLiveRamp gains after FTC approves $2.5B sale to Publicis with conditionsSeeking Alpha Tech